Brief: Biomea Fusion Announces FDA Clearance Of Investigational New Drug Application For Covalent FLT3 Inhibitor Bmf-500 In Relapsed Or Refractory Acute Leukemia
01/05/2023 13:39
May 1 (Reuters) - Biomea Fusion Inc BMEA.O :
* BIOMEA FUSION ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL
NEW
DRUG (IND) APPLICATION FOR COVALENT FLT3 INHIBITOR BMF-500 IN
RELAPSED OR REFRACTORY ACUTE LEUKEMIA
* BIOMEA FUSION ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL
NEW
DRUG (IND) APPLICATION FOR COVALENT FLT3 INHIBITOR BMF-500 IN
RELAPSED OR REFRACTORY ACUTE LEUKEMIA
Source text for Eikon: ID:nGNX17Fms9
Further company coverage: BMEA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biomea Fusion
See all newsUS RESEARCH ROUNDUP-BlackRock, Microsoft, TransDigm Group
Brief: Biomea Fusion Announces Phase 1 Results For Bmf-650, Its Investigational Next-Generation Oral Small Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion To Announce Phase I Results For Bmf-650, Its Next-Generation Oral Small-Molecule Glp-1 Receptor Agonist
Brief: Biomea Fusion Announces Termination Of Proposed Public Offering Of Securities
Brief: Biomea Fusion Announces Completion Of Enrollment In Covalent-211 Phase Ii Trial Of Icovamenib In Insulin-Deficient Type 2 Diabetes